UnitedHealth Group shares climbed more than 3%, capping an 8% rally over the past month as initial investor anxiety regarding the company’s business model dissipated. This shift toward the defensive sector mirrors a wider market trend where capital seeks refuge in predictable earnings.

AstraZeneca shares mirrored this upward trajectory, gaining 2.9% to reach $166.68. The British pharmaceutical firm announced a strategic partnership with the startup Insitro, utilizing artificial intelligence for accelerated disease research. The deal, valued at up to $1.5 billion, highlights how established drug makers are integrating advanced technology to drive long-term value while maintaining their status as safe-haven assets.